BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research note released on Friday, MarketBeat.com reports. The firm issued an outperform rating and a $163.00 price target on the stock. A number of other equities analysts also recently commented on the company. Cantor Fitzgerald reiterated an overweight […]